The Phase 3 EPIC trial is a randomized, sham-controlled, double-blind study evaluating NRTX-1001 cell therapy in adults with ...

Administering the therapy to newborn mice increased their survival, reduced the severity of their seizures and restored brain neuron excitability. The team notes that different forms of SCN1B gene ...

Discover how MR-guided focused ultrasound offers a revolutionary non-invasive treatment for tremors and epilepsy reducing ...

The Phase 3 EPIC trial is a randomized, sham-controlled, double-blind study evaluating NRTX-1001 cell therapy in adults with drug-resistant mesial temporal lobe epilepsy SAN FRANCISCO, Feb.

Subscribe for FREE Mice without the SCN1B gene experience seizures and 100 percent mortality just three weeks after birth. Using mouse models, the investigative team, led by Chunling Chen, M.D., and ...

New Delhi, February 15 (IANS) A team of researchers has developed a new gene therapy for children with Dravet syndrome -- a rare type of epilepsy in children. Dravet syndrome (DS) is a ...

Feb. 19, 2025 — New research focuses on diagnostic delays experienced by people with epilepsy, a neurological disorder characterized by unpredictable seizures that affects over 3 million people ...